Fludarabine

Generic Name: Fludarabine

Brand Names: Fludara

Drug Type: Small Molecule

Chemical Formula: C_₁₀H_₁₂FN_₅O_₄

CAS Number: 21679-14-1

Unique Ingredient Identifier: P2K93U8740

Background: Fludarabine is a chemotherapeutic agent used in the treatment of hematological malignancies. It is commonly marketed under the brand name Fludara.

Indication: For the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to or whose disease has progressed during treatment with at least one standard alkylating-agent containing regimen

Associated Conditions: B-cell chronic lymphocytic leukemia/prolymphocytic leukemia/small lymphocytic lymphoma refractory, Refractory Non-Hodgkin's lymphoma

Associated Therapies: -

Clinical Trials

Alemtuzumab and Combination Chemotherapy Followed By Donor Lymphocytes in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer

Phase 1

Completed

Conditions: Chronic Myeloproliferative Disorders
Leukemia
Lymphoma
Myelodysplastic Syndromes
Myelodysplastic/Myeloproliferative Neoplasms

First Posted Date: 2005-03-04

Last Posted Date: 2016-12-15

Lead Sponsor: Yale University

Target Recruit Count: 20

Registration Number: NCT00104975

Locations: 🇺🇸
Yale Cancer Center, New Haven, Connecticut, United States

Fludarabine Phosphate, Radiation Therapy, and Rituximab in Treating Patients Who Are Undergoing Donor Stem Cell Transplant Followed by Rituximab for High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Phase 2

Completed

Conditions: Chronic Lymphocytic Leukemia
Refractory Chronic Lymphocytic Leukemia
Stage III Small Lymphocytic Lymphoma
Stage IV Small Lymphocytic Lymphoma
Prolymphocytic Leukemia
Stage III Chronic Lymphocytic Leukemia
Recurrent Small Lymphocytic Lymphoma
Stage IV Chronic Lymphocytic Leukemia
T-Cell Large Granular Lymphocyte Leukemia

Interventions: Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
Drug: Cyclosporine
Drug: Fludarabine Phosphate
Other: Laboratory Biomarker Analysis
Drug: Mycophenolate Mofetil
Procedure: Peripheral Blood Stem Cell Transplantation
Other: Pharmacological Study
Biological: Rituximab
Radiation: Total-Body Irradiation

First Posted Date: 2005-03-04

Last Posted Date: 2019-07-11

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 66

Registration Number: NCT00104858

Locations: 🇺🇸
VA Puget Sound Health Care System, Seattle, Washington, United States
🇩🇰
Rigshospitalet University Hospital, Copenhagen, Denmark
🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

and more 2 locations

Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer

Phase 2

Completed

Conditions: Previously Treated Myelodysplastic Syndrome
Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Waldenstrom Macroglobulinemia
Childhood Myelodysplastic Syndrome
Stage II Contiguous Adult Diffuse Large Cell Lymphoma
Stage II Contiguous Adult Lymphoblastic Lymphoma
Stage II Grade 1 Contiguous Follicular Lymphoma
Stage II Grade 2 Contiguous Follicular Lymphoma
Stage II Non-Contiguous Adult Burkitt Lymphoma

Interventions: Drug: Fludarabine Phosphate
Radiation: Total-Body Irradiation
Procedure: Peripheral Blood Stem Cell Transplantation
Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
Drug: Tacrolimus
Drug: Mycophenolate Mofetil
Drug: Sirolimus

First Posted Date: 2005-03-04

Last Posted Date: 2019-10-30

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 210

Registration Number: NCT00105001

Locations: 🇩🇰
Rigshospitalet University Hospital, Copenhagen, Denmark
🇺🇸
Froedtert and the Medical College of Wisconsin, Milwaukee, Wisconsin, United States
🇩🇪
Medizinische Univ Klinik Koln, Koln, Germany

and more 8 locations

Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia in Remission

Phase 2

Withdrawn

Conditions: Adult Acute Erythroid Leukemia
Adult Acute Monoblastic and Acute Monocytic Leukemia
Adult Acute Myeloid Leukemia

First Posted Date: 2005-01-10

Last Posted Date: 2017-10-19

Lead Sponsor: Eastern Cooperative Oncology Group

Registration Number: NCT00101140

Fludarabine, Rituximab, and Alemtuzumab in Treating Patients With Chronic Lymphocytic Leukemia

Phase 2

Completed

Conditions: Stage II Chronic Lymphocytic Leukemia
Stage III Chronic Lymphocytic Leukemia
B-cell Chronic Lymphocytic Leukemia
Stage I Chronic Lymphocytic Leukemia
Stage IV Chronic Lymphocytic Leukemia

Interventions: Biological: alemtuzumab
Biological: rituximab
Drug: fludarabine phosphate

First Posted Date: 2004-12-08

Last Posted Date: 2014-05-21

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 102

Registration Number: NCT00098670

Locations: 🇺🇸
Cancer and Leukemia Group B, Chicago, Illinois, United States
🇺🇸
Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center, Columbus, Ohio, United States

Cyclophosphamide, Fludarabine, and Total-Body Irradiation Followed By Cellular Adoptive Immunotherapy, Autologous Stem Cell Transplantation, and Interleukin-2 in Treating Patients With Metastatic Melanoma

Phase 2

Completed

Conditions: Melanoma (Skin)

Interventions: Biological: aldesleukin
Biological: filgrastim
Biological: therapeutic tumor infiltrating lymphocytes
Drug: cyclophosphamide
Drug: fludarabine phosphate
Radiation: radiation therapy

First Posted Date: 2004-11-09

Last Posted Date: 2015-10-28

Lead Sponsor: National Institutes of Health Clinical Center (CC)

Target Recruit Count: 34

Registration Number: NCT00096382

Locations: 🇺🇸
NCI - Surgery Branch, Bethesda, Maryland, United States
🇺🇸
Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office, Bethesda, Maryland, United States

Fludarabine and Thalidomide in Treating Patients With Newly Diagnosed Chronic Lymphocytic Leukemia

Phase 1

Completed

Conditions: Leukemia

Interventions: Drug: fludarabine phosphate
Drug: thalidomide

First Posted Date: 2004-11-09

Last Posted Date: 2013-10-24

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 43

Registration Number: NCT00096018

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Vaccine Therapy With or Without Fludarabine in Treating Patients With Stage IV Kidney Cancer

Phase 2

Conditions: Kidney Cancer

First Posted Date: 2004-10-08

Last Posted Date: 2013-12-19

Lead Sponsor: St. Luke's Medical Center

Target Recruit Count: 28

Registration Number: NCT00093522

Locations: 🇺🇸
Vince Lombardi Cancer Clinic at Aurora St. Luke's Medical Center, Milwaukee, Wisconsin, United States
🇺🇸
Midwest Heart Surgery Institute, Limited, Milwaukee, Wisconsin, United States

Low-Dose Total-Body Irradiation and Fludarabine Phosphate Followed by Unrelated Donor Stem Cell Transplant in Treating Patients With Fanconi Anemia

Phase 1

Completed

Conditions: Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)
Fanconi Anemia
Adult Acute Myeloid Leukemia in Remission
Adult Acute Myeloid Leukemia With Del(5q)
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)
Childhood Acute Myeloid Leukemia in Remission
Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)
Childhood Myelodysplastic Syndromes

Interventions: Drug: fludarabine phosphate
Drug: cyclosporine
Radiation: total-body irradiation
Procedure: allogeneic bone marrow transplantation
Procedure: allogeneic hematopoietic stem cell transplantation
Procedure: peripheral blood stem cell transplantation
Drug: mycophenolate mofetil

First Posted Date: 2004-10-08

Last Posted Date: 2017-02-20

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 2

Registration Number: NCT00093743

Locations: 🇺🇸
Riley Hospital for Children, Indianapolis, Indiana, United States
🇺🇸
Robert H. Lurie Comprehensive Cancer Center, Chicago, Illinois, United States
🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States

and more 2 locations

Fludarabine in Treating Patients With Steroid-Resistant Chronic Graft- Versus-Host Disease

Phase 1

Conditions: Graft Versus Host Disease

First Posted Date: 2004-09-16

Last Posted Date: 2013-12-18

Lead Sponsor: Jonsson Comprehensive Cancer Center

Registration Number: NCT00004194

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy